Comparative Pharmacology
Head-to-head clinical analysis: LAZANDA versus MORPHABOND ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAZANDA versus MORPHABOND ER.
LAZANDA vs MORPHABOND ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a μ-opioid receptor agonist. It binds to μ-opioid receptors in the central nervous system, activating G-protein-coupled receptors to inhibit adenylate cyclase, reduce cAMP production, and modulate ion channels, leading to decreased neurotransmitter release (e.g., substance P, glutamate) and hyperpolarization of neurons, resulting in analgesia and sedation.
Morphine is a full opioid agonist that binds to mu-opioid receptors in the central nervous system, mimicking endogenous endorphins. Activation of mu receptors leads to G-protein-coupled inhibition of adenylyl cyclase, decreased cAMP production, closure of voltage-gated calcium channels, and opening of potassium channels. This results in reduced neuronal excitability, inhibition of neurotransmitter release (e.g., substance P, glutamate), and modulation of pain signaling pathways, producing analgesia, euphoria, and sedation.
100 mcg (one spray) intranasally as needed for breakthrough pain; may repeat once after 15-30 minutes if needed; do not exceed 2 doses per episode and 4 doses per day.
15-30 mg orally every 12 hours, titrated to effect; maximum 60 mg per dose or 120 mg daily.
None Documented
None Documented
Terminal elimination half-life: 6–10 hours (mean approximately 7 hours) following nasal administration; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 11–13 hours in adults, allowing once-daily dosing for MORPHABOND ER. In hepatic impairment, half-life may be prolonged.
Renal excretion of metabolites (mostly fentanyl metabolites, primarily norfentanyl): approximately 75%; fecal excretion: approximately 9%; less than 10% excreted as unchanged fentanyl in urine.
Approximately 90% excreted renally as morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G), with ~10% excreted unchanged. Fecal elimination accounts for <10%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic